Clinical Trials

  • Principal Investigator:

    Aya Haggiagi, MD
    The purpose of this study is to learn about the safety (the impact of the study drug on your body) and the effects of study drug PF-07799544 for specific types of cancer on the body and to find the best dose for treating certain cancers. For BRAF (B-raf proto-oncogene serine/threonine kinase) mutated solid tumors, PF-07799544 may be combined with encorafenib, also known as BRAFTOVI (an FDA-approved cancer medication). The study drug PF-07799544 is an investigational drug because it is not FDA-approved for use in this country. The study drug encorafenib is approved in this country and is...
  • Principal Investigator:

    Fabio M. Iwamoto, MD
    The purpose of this study is to find out if REC-2282, an investigational new drug, is an effective and safe treatment in patients with progressive NF2 mutated meningiomas who have either NF2 disease-related meningioma or recurrent sporadic meningiomas that have NF2 mutation. Investigational new drug means a drug that has not been approved as a marketed product (i.e., available to be prescribed or sold) by any regulatory authorities, such as the US Food and Drug Administration (FDA). REC-2282 is a potential treatment for a variety of tumors where various enzymes and proteins play a large role...
  • Principal Investigator:

    Fabio M. Iwamoto, MD
    The purpose of this study is to find out if REC-2282, an investigational new drug, is an effective and safe treatment in patients with progressive NF2 mutated meningiomas who have either NF2 disease-related meningioma or recurrent sporadic meningiomas that have NF2 mutation. Investigational new drug means a drug that has not been approved as a marketed product (i.e., available to be prescribed or sold) by any regulatory authorities, such as the US Food and Drug Administration (FDA). REC-2282 is a potential treatment for a variety of tumors where various enzymes and proteins play a large role...
  • Principal Investigator:

    Fabio M. Iwamoto, MD
    The purpose of this study is to see how safe and effective Safusidenib erbumine, the study drug, is in treating brain glioma and to find the recommended dose of the study drug for clinical studies. Safusidenib is not Food and Drug Administration (FDA) approved.
  • Principal Investigator:

    Fabio M. Iwamoto, MD
    The purpose of this study is to see how safe and effective Safusidenib erbumine, the study drug, is in treating brain glioma and to find the recommended dose of the study drug for clinical studies. Safusidenib is not Food and Drug Administration (FDA) approved.
  • Principal Investigator:

    Fabio M. Iwamoto, MD
    With this research study, we want to find out which dose of ST101 is tolerable and effective for people with different types of cancer. We also want to see what the body does to ST101, where ST101 goes in the body, and how long it stays in the body. This study is the first time we have given ST101 to humans. Drugs that can only be used in research are sometimes called 'investigational drugs.' "Investigational" means the study drug/formulation/medical device being tested is not approved by the U.S. Food and Drug Administration (FDA).
  • Principal Investigator:

    Fabio M. Iwamoto, MD
    The purpose of this study is to learn the effects of the investigational new drug, tirabrutinib, when given for the treatment of PCNSL. Investigational new drug means a drug that has not been approved as a marketed product (that is, available to be prescribed or sold) by the United States (US) Food and Drug Administration (FDA). Tirabrutinib acts by blocking an enzyme called Brutons tyrosine kinase or BTK. Some cancer cells use BTK to grow and thrive in your body. Tirabrutinib blocks BTK and may interfere with the growth of cancer cells. This study is divided into 2 parts; Part A of the study...
  • Principal Investigator:

    Fabio M. Iwamoto, MD
    The purpose of this study is to learn the effects of the investigational new drug, tirabrutinib, when given for the treatment of PCNSL. Investigational new drug means a drug that has not been approved as a marketed product (that is, available to be prescribed or sold) by the United States (US) Food and Drug Administration (FDA). Tirabrutinib acts by blocking an enzyme called Brutons tyrosine kinase or BTK. Some cancer cells use BTK to grow and thrive in your body. Tirabrutinib blocks BTK and may interfere with the growth of cancer cells. This study is divided into 2 parts; Part A of the study...
  • Principal Investigator:

    Andrew B. Lassman, MD
    The purpose of this study is to test the safety of a new vaccine, VBI-1901, and to know more about its ability to boost the response of the immune system against Cytomegalovirus. The reason for testing this vaccine in people with a brain tumor is that it might one day be used to boost the ability of the immune system to fight a certain type of brain tumor. This type of treatment for brain tumors is called immunotherapy.
  • Principal Investigator:

    Andrew B. Lassman, MD
    The purpose of this study is to test the safety of a new vaccine, VBI-1901, and to know more about its ability to boost the response of the immune system against Cytomegalovirus. The reason for testing this vaccine in people with a brain tumor is that it might one day be used to boost the ability of the immune system to fight a certain type of brain tumor. This type of treatment for brain tumors is called immunotherapy.

Pages